CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 14 pages
VFC Resolution Update: Hepatitis B Vaccine December 4, 2025National Center for Immunization & Respiratory Diseases •Red font in the presentation is used to indicate changes to the resolution in comparison to the currently approved version.Note •The purpose of this resolution is to update the Recommended Vaccination Schedule and Intervals section to reflect updated ACIP recommendations about the use of Hepatitis B vaccine. Purpose of the Resolution • All children and adolescents birth…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 5 pages
Centers for Medicare & Medicaid Services Overview of Vaccine Coverage December 2025 1 Medicaid and CHIP •Coverage of vaccines is anchored to ACIP recommendations, and the adult/pediatric vaccine schedules, which is based on those recommendations. •State Medicaid and Children’s Health Insurance Programs (CHIP) are required to cover all vaccines recommended by CDC/ACIP that are included on the adult/pediatric immunization schedules without cost sharing for most beneficiaries, including…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 76 pages
Development of the U.S. Childhood Vaccine Schedule Aaron SiriACIP Meeting, December 5, 2025With A Focus on Suggested Improvements DisclosuresManaging Partner of Siri & Glimstad LLP with 100+ professionals who handle civil rights, exemptions, immigration, employment, and injury claims related to vaccination. Author of Vaccines, Amen: The Religion of Vaccines. 2 Growth of U.S. Childhood Vaccine Schedule Growth of U.S. Vaccine Schedule…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 30 pages
Summary of two economic models for dengue vaccine TAK-003 use in Puerto Rico Advisory Committee on Immunization Practices June 22, 2023 The models summarized are currently undergoing the CDC economic review following the ACIP Guidance for Health Economics Studies, so results should be considered as preliminary.RajReni Kaul, PhD CDC/NCIRD/ISD The findings and conclusions in this presentation are those of the author(s) and do not necessarily represent the views of the Centers for Disease…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 65 pages
Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases Partial Evidence to Recommendations Framework for Dengue Vaccine TAK -003 Joshua Wong, MD ACIP June 22, 2023 Dengue Branch, CDC Goals for Partial EtRPresentation •Summarize the extent of the Work Group deliberations to date •Present three Evidence to Recommendations ( EtR) domains* •Prepare ACIP for the next meeting which will include a full EtRpresentation, proposed recommendation, and…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 6 pages
CHIKUNGUNYA VACCINES Beth Bell, MD, MPH Chair, ACIP Chikungunya Vaccines Work GroupACIP Meeting June 22, 2023 Background In February 2023, FDA accepted Valneva’s Biologics License Application (BLA) for their chikungunya vaccine and granted priority review, with licensure possible in August 2023 No chikungunya vaccine ever licensed in United States or globally No existing ACIP chikungunya vaccine recommendations Chikungunya Vaccines Work Group is developing policy options for ACIP’s …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 30 pages
National Center for Emerging and Zoonotic Infectious Diseases Value of a vaccine to prevent travel -related chikungunya for US persons Nicole Lindsey, MS CDC Deputy Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Centers for Disease Control and PreventionJune 22, 2023 Potential value of a chikungunya vaccine among international travelers (Valneva survey) 2021 online survey of 2,002 US residents aged ≥ 18 years who either travelled internationally in last 3 years or planned…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 9 pages
National Center for Emerging and Zoonotic Infectious Diseases CHIKUNGUNYA VIRUS INFECTIONS AMONG LABORATORY WORKERS Susan Hills, MBBS, MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector -Borne Diseases Fort Collins, Colorado ACIP meeting, June 22, 2023 Chikungunya virus management in the laboratory Handled at biosafety level (BSL) -3 High viral loads in blood samples increase risk for l aboratory -acquired infections1 1. Simmons G et al, Emerg…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 12 pages
National Center for Emerging and Zoonotic Infectious Diseases UPDATE AND OBSERVATIONS ON A LARGE CHIKUNGUNYA OUTBREAK IN PARAGUAY Susan Hills, MBBS, MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector -Borne Diseases Fort Collins, Colorado ACIP meeting, June 22, 2023 Chikungunya notifications* October 1, 2022 –June 3, 2023 167,239 cases Source: Ministry of Public Health and Social Welfare, Paraguay Epidemiologic weekNo. notifications *Confirmed and…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 4 pages
National Center for Emerging and Zoonotic Infectious Diseases WORK GROUP PLANS AND TIMELINES Susan Hills, MBBS, MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Centers for Disease Control and Prevention ACIP meeting June 22, 2023 Work Group timeline (tentative) Jun May Apr Mar Feb Jan Sept Jul Aug2024 Present EtRs (Today) Perceptions of chikungunya vaccine, Laboratory workers, Paraguay outbreakACIP vote on vaccine recommendations for adult travelers and laboratory…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 6 pages
1 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group Sarah S. Long, MD Chair,…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 52 pages
Economics of Pfizer maternal RSVpreF vaccine David W. Hutton, PhD, MS Associate Professor, Health Management and Policy, School of Public Health Associate Professor of Global Public Health, School of Public Health Associate Professor, Industrial and Operations Engineering, College of Engineering University of MichiganPresentation to the ACIP June 22, 2023 Research team University of Michigan •David Hutton, PhD •Lisa Prosser, PhD •Angela Rose, MPH •Kerra Mercon , MSCDC •Jefferson Jones, MD,…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 130 pages
Centers for Disease Control and Prevention Evidence to Recommendations Framework: Pfizer Maternal RSVpreF Vaccine Katherine Fleming -Dutra, MD Co-Lead, Respiratory Syncytial Virus Vaccines -Pediatric/Maternal Work Group Coronavirus and Other Respiratory Viruses Division National Center for Immunization and Respiratory Diseases June 22, 2023 2Evidence to Recommendations (EtR) Framework Policy Question ▪Should vaccination with Pfizer RSVPreF vaccine (120µg antigen, 1 dose IM given 24 –36…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 57 pages
Economics of combined use of Pfizer maternal RSVpreF vaccine and nirsevimab David W. Hutton, PhD, MS Associate Professor, Health Management and Policy, School of Public Health Associate Professor of Global Public Health, School of Public Health Associate Professor, Industrial and Operations Engineering, College of Engineering University of MichiganPresentation to the ACIP June 22, 2023 Research team University of Michigan •David Hutton, PhD •Lisa Prosser, PhD •Angela Rose, MPH •Kerra…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 11 pages
Centers for Disease Control and Prevention Clinical considerations for RSVpreF maternal vaccine and nirsevimab Jefferson Jones MD MPH FAAP CDR USPHS Co-Lead, Respiratory Syncytial Virus Vaccines -Pediatric/Maternal Work Group Coronavirus and Other Respiratory Viruses Division National Center for Immunization and Respiratory Diseases June 22, 2023 2Policy questions for ACIP vote ▪Should vaccination with Pfizer RSVPreF vaccine (120µg antigen, 1 dose IM given 24 - 36 weeks gestation) be…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 17 pages
National Center for Emerging and Zoonotic Infectious Diseases Mpox Vaccine Work Group ACIP Meeting June 23, 2023 Pablo Sanchez MD The Ohio State University−Nationwide Children’s Hospital Chair, ACIP Mpox Work Group Mpox outbreaks ▪Before 2022, rare outside of Africa ▪In Africa, have involved 2 clades: –Clade I (previously Congo Basin Clade) –Clade II (previously West African Clade) ▪In United States, have involved Clade II –Clade IIa: 2003 U.S. outbreak associated with pet prairie dogs –Clade…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 35 pages
National Center for Emerging and Zoonotic Infectious Diseases Updates from the 2022 –2023 U.S. Mpox Outbreak: Epidemiology, Vaccine Safety, and Vaccine Effectiveness ACIP Meeting June 23, 2023Faisal Syed Minhaj, PharmD, MPH, DABAT Epidemic Intelligence Service Officer Poxvirus and Rabies Branch United States Mpox Case Counts April 2022 –June 2023 https://www.cdc.gov/poxvirus/mpox/response/2022/mpx -trends.html United States Mpox Case Counts January 1 –June 6, 2023 Uptick in cases in …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 25 pages
National Center for Emerging and Zoonotic Infectious Diseases Use of JYNNEOS During Mpox Outbreaks: Clinical Guidance Agam Rao, MD CAPT, US Public Health Service Medical Officer Poxvirus and Rabies Branch Advisory Committee on Immunization Practices June 23, 2023 Vote passed during February 2023 ACIP meeting ACIP recommends the 2 -dose* JYNNEOS vaccine series for persons aged 18 years and older at risk of mpox during an mpox outbreak§ *Dose 2 administered one…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 24 pages
National Center for Emerging and Zoonotic Infectious Diseases Considerations for long -term protection against mpox Advisory Committee on Immunization Practices June 23, 2023Agam Rao, MD CAPT, US Public Health Service Medical Officer Poxvirus and Rabies Branch CDC collaborative studies examining serologic response to JYNNEOS vaccinations Study Goals Timepoints/Duration Participant Information •DRC •Healthcare personnel •Democratic Republic of the Congo, Tshuapa Province•Safety…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 5 pages
National Center for Immunization & Respiratory Diseases ACIP Meningococcal Vaccines Work Group Introduction Katherine Poehling, MD, MPH Work Group Chair June 23, 2023 2Meningococcal Vaccines Work Group ▪ ACIP Members on the WG –Kathy Poehling (Chair) –Lynn Bahta –Jamie Loehr ▪ Ex Officio WG Members –Margaret Bash (FDA) –Mark Connelly (FDA) –Francisco Leyva (NIH) ▪ WG Liaisons and Consultants –Amra Resic (AAFP) –Samir Shah (AAP) –Sharon McMullen (ACHA) –Cacky Tate (AIM) –Paul Cieslak (CSTE)…